Intercept’s NASH NDA Positions OCA For May 2020 Approval, Then Launch
Executive Summary
Intercept hopes to be first to market in NASH with an indication to treat fibrosis. It also is enrolling a study to show a benefit in NASH patients with cirrhosis.